CPN Biosciences
Organogenesis is a leading regenerative medicine company dedicated to empowering healing through innovative tissue solutions. Founded in 1985 as a spin-off from MIT, the company specializes in advanced wound care, surgical, and sports medicine products. With a mission to improve lives and lower healthcare costs, Organogenesis develops, manufactures, and sells regenerative tissue products, including FDA-approved brands like Apligraf® and Dermagraft®. The company emphasizes responsibility, ethics, and compliance, actively contributing to community programs and scientific communities. Its global headquarters is in Canton, MA, with additional facilities in San Diego, CA, Birmingham, AL, and St. Petersburg, FL.
Industries
Nr. of Employees
medium (51-250)
Products
Dehydrated amnion allografts (single- and dual-layer formats)
Thin, flexible dehydrated amniotic membrane products that provide a protective barrier and ECM scaffold to support healing; ready-to-use with ambient storage and terminal sterilization.
Multi-layer placental allografts (amnion + chorion)
Multi-layer dehydrated placental products that retain all native tissue layers to provide a thicker ECM scaffold and protective barrier for wound healing.
Fresh-preserved placental allografts with viable cell retention
Placental-derived allografts preserved in a fresh state to retain living cells, intact ECM, and endogenous growth factors for wound and surgical applications (not dehydrated or frozen).
Bioengineered 3-D living-cell skin constructs
Three-dimensional skin substitutes that deliver living human cells within a scaffold to accelerate healing in chronic wounds.
Micronized wound matrix formulations
Micronized wound matrix materials formulated for ease of application to wound beds to support granulation and tissue repair.
Dehydrated amnion allografts (single- and dual-layer formats)
Thin, flexible dehydrated amniotic membrane products that provide a protective barrier and ECM scaffold to support healing; ready-to-use with ambient storage and terminal sterilization.
Multi-layer placental allografts (amnion + chorion)
Multi-layer dehydrated placental products that retain all native tissue layers to provide a thicker ECM scaffold and protective barrier for wound healing.
Fresh-preserved placental allografts with viable cell retention
Placental-derived allografts preserved in a fresh state to retain living cells, intact ECM, and endogenous growth factors for wound and surgical applications (not dehydrated or frozen).
Bioengineered 3-D living-cell skin constructs
Three-dimensional skin substitutes that deliver living human cells within a scaffold to accelerate healing in chronic wounds.
Micronized wound matrix formulations
Micronized wound matrix materials formulated for ease of application to wound beds to support granulation and tissue repair.
Services
Benefit verification, coding guidance, and reimbursement inquiry assistance for physician and facility providers.
Order placement, standing orders, returns processing, free-shipping logistics, and order tracking supported by a dedicated customer service center.
Medical affairs and technical teams provide clinician education, scientific resources, research support, and a medical information contact point.
Implementation and governance of compliance-related policies, employee training, monitoring, auditing, confidential reporting channels, and corrective action processes.
Quality management and release assurance processes to ensure products meet specified quality and safety standards prior to distribution.
Benefit verification, coding guidance, and reimbursement inquiry assistance for physician and facility providers.
Order placement, standing orders, returns processing, free-shipping logistics, and order tracking supported by a dedicated customer service center.
Medical affairs and technical teams provide clinician education, scientific resources, research support, and a medical information contact point.
Implementation and governance of compliance-related policies, employee training, monitoring, auditing, confidential reporting channels, and corrective action processes.
Quality management and release assurance processes to ensure products meet specified quality and safety standards prior to distribution.
Expertise Areas
- Regenerative medicine product development
- Allograft processing and tissue preservation
- Commercial-scale biologics manufacturing
- Clinical trial support and medical affairs
Key Technologies
- Placental and amniotic allografts
- Extracellular matrix (ECM) scaffolds
- Bioengineered 3D living-cell skin constructs
- Dehydration and ambient-stable preservation methods
News & Updates
Organogenesis Smithfield will add manufacturing, R&D, and logistics capabilities supporting existing and planned products designed to advance innovation and regenerative solutions.
FDA Approvals of Apligraf® and Dermagraft®
Apligraf® was FDA-approved in 1998 for venous leg ulcers and in 2000 for diabetic foot ulcers. Dermagraft® was acquired in 2014 for chronic diabetic foot ulcers.
NASDAQ Trading
Organogenesis began trading on the NASDAQ Stock Market in 2019.
Launch of Novachor™ and PuraPly® MZ
Innovative products supporting wound healing and tissue regeneration launched in 2021 and 2022 respectively.
Organogenesis Smithfield will add manufacturing, R&D, and logistics capabilities supporting existing and planned products designed to advance innovation and regenerative solutions.
FDA Approvals of Apligraf® and Dermagraft®
Apligraf® was FDA-approved in 1998 for venous leg ulcers and in 2000 for diabetic foot ulcers. Dermagraft® was acquired in 2014 for chronic diabetic foot ulcers.
NASDAQ Trading
Organogenesis began trading on the NASDAQ Stock Market in 2019.
Launch of Novachor™ and PuraPly® MZ
Innovative products supporting wound healing and tissue regeneration launched in 2021 and 2022 respectively.